Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

EnligHTN German Observational Study of Renal Denervation for Uncontrolled Hypertension

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
St. Jude Medical Identifier:
First received: November 21, 2013
Last updated: October 11, 2016
Last verified: October 2016
The purpose of this observational study is to further evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with uncontrolled hypertension in clinical routine practice.

Uncontrolled Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: This is a Post Market, Multi-center, Open Label, Observational Study. Approximately 500 Subjects With Uncontrolled Hypertension Will Undergo Renal Artery Ablation

Further study details as provided by St. Jude Medical:

Primary Outcome Measures:
  • Mean reduction in office Systolic Blood Pressure at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 25
Study Start Date: October 2013
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Detailed Description:
This is a post market, multi-center, open label, observational study. Approximately 500 subjects with uncontrolled hypertension will undergo renal artery ablation at approximately 40 investigational sites located in Germany and will be followed for 1 year post procedure.The expected duration of the investigation will be approximately 4 years.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The patient population enrolled in this investigation will consist of males and females with uncontrolled hypertension who meet all inclusion criteria, and none of the exclusion criteria.

Inclusion Criteria:

  • Subject is planned to undergo a renal denervation procedure for the treatment of hypertension
  • Subject is ≥18 years of age at time of consent
  • Subject must be able and willing to provide written informed consent
  • Subject must be able and willing to comply with the required follow-up schedule
  • Subject has office Systolic Blood Pressure (SBP) ≥ 140 mmHg
  • Subject has established hypertension (diagnosed ≥12 months prior to baseline) and is on a guideline based drug regimen at a stable (≥ 14 days) and a fully tolerated dose consisting of ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE-I/ Angiotensin Receptor Blocker (ARB), Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs

Exclusion Criteria:

  • Subject has known significant renovascular abnormalities such as renal artery stenosis > 30%
  • Subject has undergone prior renal angioplasty, renal denervation, indwelling renal stents, and/or abdominal aortic stent grafts
  • Subject has a history of hemodynamically significant valvular heart disease
  • Subject has blood clotting abnormalities
  • Subject life expectancy is < 12 months, as determined by the Study Investigator
  • Subject is participating in another clinical study which has the potential
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01996033

Kliniken Villingen-Schwenningen
Villingen-Schwenningen, Baden-Wurttemberg, Germany, 78052
Kliniken Oberallgäu gGmbH Klinik Immenstadt
Immenstadt, Bayern, Germany, 87509
Immanuelklinikum Bernau und Herzzentrum Brandenburg
Bernau, Brandenburg, Germany, 16321
Klinikum Ernst von Bergmann
Potsdam, Brandenburg, Germany, 14467
Asklepios Schwalm-Eder-Kliniken GmbH
Schwalmstadt, Hesse, Germany, 34613
Klinikum Oldenburg gGmbH
Oldenburg, Niedersachsen, Germany, 26133
Elisabeth-Krankenhaus Essen
Essen, Nordrhein-Westfalen, Germany, 45138
Medizinische Einrichtungen der Universität Düsseldorf
Düsseldorf, Northrhine-Westphalia, Germany, 40225
Kardiologische Praxis Wuppertal
Wuppertal, Northrhine-Westphalia, Germany, 42103
Universitätsklinikum Leipzig
Leipzig, Saxony, Germany, 04103
Augusta-Krankenhaus Düsseldorf
Düsseldorf, Germany, 40472
Diakonie-Klinikum Schwäbisch Hall gGmbH
Schwäbisch Hall, Germany, 74523
Sponsors and Collaborators
St. Jude Medical
Principal Investigator: Christoph K Naber, MD Elisabeth-Krankenhaus Essen, Germany
  More Information

Responsible Party: St. Jude Medical Identifier: NCT01996033     History of Changes
Other Study ID Numbers: CV-12-064-GE-HT 
Study First Received: November 21, 2013
Last Updated: October 11, 2016
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by St. Jude Medical:
uncontrolled hypertension
Renal Denervation

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on October 28, 2016